Cardene SR (Page 4 of 4)
DOSAGE AND ADMINISTRATION
The dose of CARDENE SR should be individually adjusted according to the blood pressure response beginning with 30 mg two times daily. The effective doses in clinical trials have ranged from 30 mg to 60 mg two times daily. The maximum blood pressure lowering effect at steady-state is sustained from 2 hours until 6 hours after dosing.
When initiating therapy or upon increasing dose, blood pressure should be measured 2 to 4 hours after the first dose or dose increase, as well as at the end of a dosing interval.
The total daily dose of immediate release nicardipine (CARDENE) may not be a useful guide to judging the effective dose of CARDENE SR. Patients currently receiving immediate release nicardipine may be titrated with CARDENE SR starting at their current total daily dose of immediate release nicardipine and then reexamined to assess the adequacy of blood pressure control.
Concomitant Use With Other Antihypertensive Agents:
- : CARDENE may be safely coadministered with thiazide
diuretics.
Diuretics
- : CARDENE may be safely coadministered with beta-blockers (see ). Beta-BlockersDrug Interactions
Special Patient Populations
Although there is no evidence that CARDENE SR impairs renal function, careful dose titration beginning with 30-mg CARDENE SR bid is advised (see ). Renal Insufficiency: PRECAUTIONS
CARDENE SR has not been studied in patients with severe liver impairment (see ). Hepatic Insufficiency: PRECAUTIONS
Caution is advised when titrating CARDENE SR dosage in patients with congestive heart failure (see ). Congestive Heart Failure: WARNINGS
HOW SUPPLIED
NDC:68151-0089-0 in a PACKAGE of 1 CAPSULE, EXTENDED RELEASES
Nicardipine HCL 30 mg SR caps
Label Image CARDENE
SR nicardipine hydrochloride capsule, extended release | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
Labeler — Carilion Materials Management (079239644) |
Registrant — Carilion Materials Management (079239644) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Carilion Materials Management | 079239644 | REPACK (68151-0089) |
Revised: 08/2016 Carilion Materials Management
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.